Global Anti-Peptic Ulcer Drugs Market Insights, Forecast to 2025
Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
China’s anti-trust crackdown on foreign pharmaceutical companies has left many foreign investors in the healthcare industry shocked. The Chinese government has had no qualms about openly stating that it prefers hospitals to purchase from domestic producers. That said, China’s homegrown manufacturers of medical devices and medicine still lack the sophistication to produce many of the more advanced health care products the country needs. Amid rising living standards and an aging population, China’s healthcare needs are set to rise sharply in the coming years.
In April 2015, China amended its Drug Administration Law, introducing two major changes.
The first is a simplification of the company set-up procedure for pharmaceutical companies. Prior to the amendment, investors that wanted to manufacture or distribute pharmaceuticals needed to have a Drug Manufacturing License or a Drug Distribution License before applying for a business license. Now, investors may apply for these after the company has been set up, significantly speeding up the incorporation process.
More importantly, the amendment removes the price controls that the Chinese government had in place for medicines. As of the year 2000, medicines that were listed on the government’s Medical Insurance Catalog, and those medicines on which there was a monopoly, had their prices fixed or guided by the government. About 23 percent of the medicines on the Chinese market had government fixed or guided prices. The price of other medicines was left to market forces. While these price restrictions are now fully removed, companies still need to abide by China’s anti-trust laws. Companies abusing their dominant market position are still punishable under Chinese law.
While recent moves have made it easier for foreign investors to introduce new medical products to the Chinese market, the Chinese government has at the same time placed restraints on advertising healthcare products. The final text of the revised Advertising Law was released by the National People’s Congress, China main legislative body, in late April 2015. The law comes into force in September 2015.
The 2015 Advertising Law has special stipulations about advertising for medicine and medical devices. For one, advertising for anesthetics, psychotropic drugs, toxic and radioactive drugs for medical use is not allowed, nor is advertisement for drugs, treatment plans and medical devices to combat drug addiction. Advertising for prescription drugs other than those mentioned previously is only allowed in professional medical journals.
The content for medical advertisements is regulated as well. Any advertisement for drugs, medical treatment or medical devices may not contain the following:
The global Anti-Peptic Ulcer Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Anti-Peptic Ulcer Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Anti-Peptic Ulcer Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Anti-Peptic Ulcer Drugs in these regions.
This research report categorizes the global Anti-Peptic Ulcer Drugs market by top players/brands, region, type and end user. This report also studies the global Anti-Peptic Ulcer Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AstraZeneca
Ask-pharm
Takeda
Yangtze River Pharm
Shandong Luoxin
Huadong Medicine
Changzhou Siyao
Beijing Yuekang
Guangdong Dahua
Xian Janssen
Market size by Product
Proton Pump Inhibitors (PPIs)
Potassium-Competitive Acid Blockers (P-CAB)
Antacids
H2 Antagonists
Ulcer Protective Drugs
Market size by End User
Gastritis
Gastric Ulcers
Duodenal Ulcers
Gastroesophageal Reflux Disease (GERD)
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Anti-Peptic Ulcer Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Anti-Peptic Ulcer Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Anti-Peptic Ulcer Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Anti-Peptic Ulcer Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Anti-Peptic Ulcer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Anti-Peptic Ulcer Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
China’s anti-trust crackdown on foreign pharmaceutical companies has left many foreign investors in the healthcare industry shocked. The Chinese government has had no qualms about openly stating that it prefers hospitals to purchase from domestic producers. That said, China’s homegrown manufacturers of medical devices and medicine still lack the sophistication to produce many of the more advanced health care products the country needs. Amid rising living standards and an aging population, China’s healthcare needs are set to rise sharply in the coming years.
In April 2015, China amended its Drug Administration Law, introducing two major changes.
The first is a simplification of the company set-up procedure for pharmaceutical companies. Prior to the amendment, investors that wanted to manufacture or distribute pharmaceuticals needed to have a Drug Manufacturing License or a Drug Distribution License before applying for a business license. Now, investors may apply for these after the company has been set up, significantly speeding up the incorporation process.
More importantly, the amendment removes the price controls that the Chinese government had in place for medicines. As of the year 2000, medicines that were listed on the government’s Medical Insurance Catalog, and those medicines on which there was a monopoly, had their prices fixed or guided by the government. About 23 percent of the medicines on the Chinese market had government fixed or guided prices. The price of other medicines was left to market forces. While these price restrictions are now fully removed, companies still need to abide by China’s anti-trust laws. Companies abusing their dominant market position are still punishable under Chinese law.
While recent moves have made it easier for foreign investors to introduce new medical products to the Chinese market, the Chinese government has at the same time placed restraints on advertising healthcare products. The final text of the revised Advertising Law was released by the National People’s Congress, China main legislative body, in late April 2015. The law comes into force in September 2015.
The 2015 Advertising Law has special stipulations about advertising for medicine and medical devices. For one, advertising for anesthetics, psychotropic drugs, toxic and radioactive drugs for medical use is not allowed, nor is advertisement for drugs, treatment plans and medical devices to combat drug addiction. Advertising for prescription drugs other than those mentioned previously is only allowed in professional medical journals.
The content for medical advertisements is regulated as well. Any advertisement for drugs, medical treatment or medical devices may not contain the following:
The global Anti-Peptic Ulcer Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Anti-Peptic Ulcer Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Anti-Peptic Ulcer Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Anti-Peptic Ulcer Drugs in these regions.
This research report categorizes the global Anti-Peptic Ulcer Drugs market by top players/brands, region, type and end user. This report also studies the global Anti-Peptic Ulcer Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AstraZeneca
Ask-pharm
Takeda
Yangtze River Pharm
Shandong Luoxin
Huadong Medicine
Changzhou Siyao
Beijing Yuekang
Guangdong Dahua
Xian Janssen
Market size by Product
Proton Pump Inhibitors (PPIs)
Potassium-Competitive Acid Blockers (P-CAB)
Antacids
H2 Antagonists
Ulcer Protective Drugs
Market size by End User
Gastritis
Gastric Ulcers
Duodenal Ulcers
Gastroesophageal Reflux Disease (GERD)
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Anti-Peptic Ulcer Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Anti-Peptic Ulcer Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Anti-Peptic Ulcer Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Anti-Peptic Ulcer Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Anti-Peptic Ulcer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Anti-Peptic Ulcer Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
